Literature DB >> 17224216

Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.

Rob J Vandebriel1, Eric R Gremmer, Jolanda P Vermeulen, Sandra M M Hellwig, Jan A M A Dormans, Paul J M Roholl, Frits R Mooi.   

Abstract

While evaluating vaccine efficacy against clinical Bordetella pertussis isolates in mice, after challenge vaccinated mice showed increased lung pathology with eosinophilia, compared to challenged, non-vaccinated animals. This led us to study bacterial clearance, lung pathology, lung TNF-alpha expression, and parameters of immediate hypersensitivity (IH), being serum IgE levels, eosinophil numbers in the bronchoalveolar lavage fluid, and ex vivo IL-4, IL-5, IL-10, IL-13, and IFN-gamma production by the bronchial lymph node cells. BALB/c mice received a combined Diphtheria (D), Tetanus (T), Poliomyelitis, and whole-cell Pertussis vaccine (WCV), a combined D, T, and three-component acellular Pertussis vaccine (ACV), aluminium hydroxide adjuvant, or PBS, 28 and 14 days before B. pertussis infection. Similarly treated non-infected mice were taken as a control. Infection induced pathology; this induction was stronger after (especially WCV) vaccination. WCV but not ACV vaccination induced TNF-alpha expression after challenge. After challenge, IH parameters were strongly increased by (especially ACV) vaccination. Vaccinated IL-4 KO mice showed similar clearance and pathology, in the absence of IgE and with reduced numbers of eosinophils. Vaccinated (Th1-deficient) T-bet KO mice showed reduced clearance and similar pathology. In summary, after challenge vaccination increased lung pathology, TNF-alpha expression (only WCV), and IH parameters. Th1 cells were critical for clearance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17224216     DOI: 10.1016/j.vaccine.2005.09.062

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymph node and lung allergy models.

Authors:  Rob J Vandebriel; Eric R Gremmer; Michiel van Hartskamp; Jan A M A Dormans; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

2.  Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.

Authors:  Jeroen Geurtsen; H Alexander Banus; Eric R Gremmer; Henke Ferguson; Liset J J de la Fonteyne-Blankestijn; Jolanda P Vermeulen; Jan A M A Dormans; Jan Tommassen; Peter van der Ley; Frits R Mooi; Rob J Vandebriel
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 3.  Symptomatic treatment of the cough in whooping cough.

Authors:  Kay Wang; Silvana Bettiol; Matthew J Thompson; Nia W Roberts; Rafael Perera; Carl J Heneghan; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2014-09-22

4.  Statins accelerate the onset of collagen type II-induced arthritis in mice.

Authors:  Rob J Vandebriel; Hilda J I De Jong; Eric R Gremmer; Olaf H Klungel; Jan-Willem Cohen Tervaert; Wout Slob; Jan Willem Van Der Laan; Henk Van Loveren
Journal:  Arthritis Res Ther       Date:  2012-04-26       Impact factor: 5.156

5.  Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection.

Authors:  Noelia Olivera; Celina E Castuma; Daniela Hozbor; María E Gaillard; Martín Rumbo; Ricardo M Gómez
Journal:  Biomed Res Int       Date:  2014-05-13       Impact factor: 3.411

6.  The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.

Authors:  Sander Banus; Rachel M Stenger; Eric R Gremmer; Jan A M A Dormans; Frits R Mooi; Tjeerd G Kimman; Rob J Vandebriel
Journal:  BMC Immunol       Date:  2008-05-22       Impact factor: 3.615

7.  Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats.

Authors:  Rob J Vandebriel; Elisa Cm Tonk; Liset J de la Fonteyne-Blankestijn; Eric R Gremmer; Henny W Verharen; Leo T van der Ven; Henk van Loveren; Wim H de Jong
Journal:  Part Fibre Toxicol       Date:  2014-05-07       Impact factor: 9.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.